SciBX: Science-Business eXchange Contents: March 21 2013, Volume 6 / Issue 11

TABLE OF CONTENTS March 21 2013, Volume 6 / Issue 11 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Hepatic disease Infectious disease Various The Distillery: Techniques Assays and screens Drug delivery Drug platforms Markers Advertisement BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The December 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a special feature on China's emerging biotech industry. This week, find out about how you can collaborate with Genewiz, Inc. Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer  Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.  SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Applying high throughput to CLL Chris Cain doi:10.1038/scibx.2013.253 Boston researchers have shown how cancer genome evolution alters clinical outcomes in chronic lymphocytic leukemia, and a Michigan team has identified a new transcriptional fusion that could contribute to CLL. Both studies could guide the development of new diagnostics and therapeutics for the blood cancer. Full Text | PDF Targets and Mechanisms Top Trapping influenza neuraminidase Lev Osherovich doi:10.1038/scibx.2013.254 A team from The University of British Columbia has used a mechanism-based approach to design irreversible inhibitors of influenza virus neuraminidase. The compounds are being developed by the venture arm of The Centre for Drug Research and Development, a public-private partnership that commercializes discoveries from Canadian researchers. Full Text | PDF Understanding fibrosis Tracey Baas doi:10.1038/scibx.2013.255 Researchers from The University of Alabama at Birmingham have shown a therapeutic effect of Rho kinase inhibitors in idiopathic pulmonary fibrosis. Although the results suggest a repurposing opportunity for the molecules, a lung-specific formulation of the inhibitors will be required to avoid systemic side effects. Full Text | PDF Tools Top Nanoparticles for lupus Lauren Martz doi:10.1038/scibx.2013.256 A Yale group has designed a nanoparticle that selectively delivered an immunosuppressant to immune cells and improved survival in mouse models of lupus. The platform has been exclusively licensed to Immunova, which is selecting an anti-inflammatory compound to take into the clinic. Full Text | PDF Distillery: Therapeutics Cancer Top Protein kinase Cι (PRKCI; aPKC-ι/λ); sonic hedgehog homolog (SHH) doi:10.1038/scibx.2013.257 Studies in vitro, in mice and in human tissue suggest inhibiting PRKCI could help treat SHH-driven BCC. Full Text | PDF IL-11 doi:10.1038/scibx.2013.258 Mouse and cell culture studies suggest inhibiting IL-11 signaling could help treat hypoxic solid tumors. Full Text | PDF Nicotinamide N-methyltransferase (NNMT) doi:10.1038/scibx.2013.259 Cell culture studies suggest inhibiting NNMT could help treat cancer. Full Text | PDF Tubulin doi:10.1038/scibx.2013.260 In vitro and mouse studies identified tubulin polymerization inhibitors that could help treat cancer. Full Text | PDF Prion protein (PRNP; PrP; CD230) doi:10.1038/scibx.2013.261 Patient sample and mouse studies suggest inhibiting PRNP could help treat metastatic colorectal cancer (CRC). Full Text | PDF Glypican 3 (GPC3) doi:10.1038/scibx.2013.262 In vitro and mouse studies identified an anti-GPC3 antibody that could help treat hepatocellular carcinoma (HCC). Full Text | PDF CD56 doi:10.1038/scibx.2013.263 Patient sample and mouse studies suggest CD56+ NK cells could help treat neuroblastoma. Full Text | PDF K-Ras; 3-phosphoinositide–dependent protein kinase-1 (PDPK1; PDK1) doi:10.1038/scibx.2013.264 Mouse studies suggest inhibiting PDK1 could help prevent mutant K-Ras-driven pancreatic ductal adenocarcinomas (PDACs). Full Text | PDF Fibroblast growth factor 19 (FGF19) doi:10.1038/scibx.2013.265 Cell culture and mouse studies suggest inhibiting FGF19 could help treat prostate cancer. Full Text | PDF Hepatic disease Top Farnesoid X receptor (FXR; NR1H4); G protein–coupled bile acid receptor 1 (GPBAR1; TGR5) doi:10.1038/scibx.2013.266 Mouse studies suggest the FXR and TGR5 dual agonist INT-767 could help treat nonalcoholic fatty liver disease (NAFLD). Full Text | PDF Infectious disease Top Interferon-ε (IFNE; IFNε) doi:10.1038/scibx.2013.267 Mouse studies suggest increasing IFNE might help prevent sexually transmitted infections. Full Text | PDF Protectin D1 (PD1) doi:10.1038/scibx.2013.268 In vitro and mouse studies suggest PD1 could help treat influenza. Full Text | PDF IL-1β; IL-18; NLR family CARD domain containing 4 (NLRC4); caspase-1 (CASP1) doi:10.1038/scibx.2013.269 Mouse studies suggest inhibiting inflammasome activation could help treat Pseudomonas aeruginosa pneumonia. Full Text | PDF Various Top AMP-activated protein kinase (AMPK); toll-like receptor 9 (TLR9) doi:10.1038/scibx.2013.270 Cell culture studies suggest activating TLR9 could help protect cardiomyocytes and neurons from stress-induced damage. Full Text | PDF Distillery: Techniques Assays and screens Top An automated microfluidic tissue processor (MTP) for immunohistochemistry doi:10.1038/scibx.2013.271 An automated MTP could allow immunohistochemistry to detect cancer biomarkers. Full Text | PDF Drug delivery Top Formulation of T cell vaccines for cancer doi:10.1038/scibx.2013.272 Mouse studies suggest saline formulations of T cell–targeted cancer vaccines could provide greater antitumor activity than conventional adjuvant carriers. Full Text | PDF Nanogel-mediated delivery of anti-inflammatory therapeutics doi:10.1038/scibx.2013.273 Nanogel-mediated delivery of anti-inflammatory therapeutics could help treat autoimmune diseases such as lupus. Full Text | PDF Drug platforms Top Bacterial synthesis of small interfering RNA doi:10.1038/scibx.2013.274 siRNA synthesized in bacteria could have better potency than chemically synthesized siRNA. Full Text | PDF Controlled Fab-arm exchange (cFAE) approach to develop bispecific antibodies for therapeutic use doi:10.1038/scibx.2013.275 In vitro and mouse studies identified a method to develop bispecific antibodies as therapeutics. Full Text | PDF Markers Top Carbamylated serum albumin as a risk factor for mortality in end-stage renal disease (ESRD) doi:10.1038/scibx.2013.276 Carbamylated serum albumin could be a useful marker of increased mortality risk in patients with ESRD. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.